Pacific Biosciences Of California (PACB) FCF Margin Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Pacific Biosciences Of California | 481.66 Mn | 205.70 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,733.00 |
| Dec 31, 2025 | 817.00 |
| Sep 30, 2025 | 4,769.00 |
| Jun 30, 2025 | 6,591.00 |
| Mar 31, 2025 | -60,473.00 |
| Dec 31, 2024 | -1,667.00 |
| Sep 30, 2024 | -2,924.00 |
| Jun 30, 2024 | -8,098.00 |
| Mar 31, 2024 | -4,326.00 |
| Dec 31, 2023 | -458.00 |
| Sep 30, 2023 | -3,995.00 |
| Jun 30, 2023 | -1,904.00 |
| Mar 31, 2023 | -15,425.00 |
| Dec 31, 2022 | -15,409.00 |
| Sep 30, 2022 | -11,851.00 |
| Jun 30, 2022 | -10,110.00 |
| Mar 31, 2022 | -17,158.00 |
| Dec 31, 2021 | -3,546.00 |
| Jun 30, 2021 | 4,806.00 |
| Mar 31, 2021 | 2,729.00 |
| Dec 31, 2020 | -4,842.00 |
| Sep 30, 2020 | 2,048.00 |
| Jun 30, 2020 | -10,729.00 |
| Mar 31, 2020 | 62,198.00 |
| Dec 31, 2019 | 2,807.00 |
| Sep 30, 2019 | -5,139.00 |
| Jun 30, 2019 | 4,948.00 |
| Mar 31, 2019 | -1,801.00 |
| Dec 31, 2018 | 6,315.00 |
| Sep 30, 2018 | -32,778.00 |
| Jun 30, 2018 | 20,244.00 |
| Mar 31, 2018 | 22,167.00 |
| Dec 31, 2017 | 23,224.00 |
| Sep 30, 2017 | 56,354.00 |
| Jun 30, 2017 | 24,982.00 |
| Mar 31, 2017 | 9,783.00 |
| Dec 31, 2016 | -1,154.00 |
| Sep 30, 2016 | 19,354.00 |
| Jun 30, 2016 | 1.81 Mn |
| Mar 31, 2016 | 1.28 Mn |
| Dec 31, 2015 | 1.44 Mn |
| Sep 30, 2015 | 1.55 Mn |